Tags

Type your tag names separated by a space and hit enter

Paradoxical Erythema Reaction of Long-term Topical Brimonidine Gel for the Treatment of Facial Erythema of Rosacea.
J Drugs Dermatol. 2016 Jun 01; 15(6):763-5.JD

Abstract

In 2013 brimonidine tartrate gel 0.33% (Mirvaso Gel, Galderma Laboratories, LP, Fort Worth, TX) was approved by the US Food and Drug Administration for the treatment of facial erythema of rosacea. It is the first and only drug on the market to address the hallmark redness of this chronic, inflammatory disease. Commonly reported adverse events include erythema/flushing worse than at baseline, most often occurring with the first application. We report a unique case of facial erythema of rosacea that responded to brimonidine gel with effective blanching for two years until the patient developed a paradoxical erythema reaction. This is an adverse reaction physicians should be aware of with continued prescription of brimonidine gel for their rosacea patients.<br /><br /> <em>J Drugs Dermatol</em>. 2016;15(6):763-765.

Authors

Lowe E
No affiliation info available
Lim S
No affiliation info available

MeSH

Administration, CutaneousAdultBrimonidine TartrateDrug Administration ScheduleErythemaFemaleGelsHumansRosaceaTreatment Outcome

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

27272086

Citation

Lowe, Erin, and Scott Lim. "Paradoxical Erythema Reaction of Long-term Topical Brimonidine Gel for the Treatment of Facial Erythema of Rosacea." Journal of Drugs in Dermatology : JDD, vol. 15, no. 6, 2016, pp. 763-5.
Lowe E, Lim S. Paradoxical Erythema Reaction of Long-term Topical Brimonidine Gel for the Treatment of Facial Erythema of Rosacea. J Drugs Dermatol. 2016;15(6):763-5.
Lowe, E., & Lim, S. (2016). Paradoxical Erythema Reaction of Long-term Topical Brimonidine Gel for the Treatment of Facial Erythema of Rosacea. Journal of Drugs in Dermatology : JDD, 15(6), 763-5.
Lowe E, Lim S. Paradoxical Erythema Reaction of Long-term Topical Brimonidine Gel for the Treatment of Facial Erythema of Rosacea. J Drugs Dermatol. 2016 Jun 1;15(6):763-5. PubMed PMID: 27272086.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Paradoxical Erythema Reaction of Long-term Topical Brimonidine Gel for the Treatment of Facial Erythema of Rosacea. AU - Lowe,Erin, AU - Lim,Scott, PY - 2016/6/9/entrez PY - 2016/6/9/pubmed PY - 2017/4/27/medline SP - 763 EP - 5 JF - Journal of drugs in dermatology : JDD JO - J Drugs Dermatol VL - 15 IS - 6 N2 - In 2013 brimonidine tartrate gel 0.33% (Mirvaso Gel, Galderma Laboratories, LP, Fort Worth, TX) was approved by the US Food and Drug Administration for the treatment of facial erythema of rosacea. It is the first and only drug on the market to address the hallmark redness of this chronic, inflammatory disease. Commonly reported adverse events include erythema/flushing worse than at baseline, most often occurring with the first application. We report a unique case of facial erythema of rosacea that responded to brimonidine gel with effective blanching for two years until the patient developed a paradoxical erythema reaction. This is an adverse reaction physicians should be aware of with continued prescription of brimonidine gel for their rosacea patients.<br /><br /> <em>J Drugs Dermatol</em>. 2016;15(6):763-765. SN - 1545-9616 UR - https://www.unboundmedicine.com/medline/citation/27272086/Paradoxical_Erythema_Reaction_of_Long_term_Topical_Brimonidine_Gel_for_the_Treatment_of_Facial_Erythema_of_Rosacea_ DB - PRIME DP - Unbound Medicine ER -